Education
About Us
Working with TipRanks
Follow Us
TMS Co., Ltd. (JP:4891)
:4891
Top Page
TMS Co., Ltd.
(4891)
Select Model
Select Model
Rating:44Neutral
Price Target:
¥125.00
▼(-3.10% Downside)
The score is held down primarily by weak financial performance (multi-year zero revenue, ongoing losses, and negative operating/free cash flow). Technicals add pressure with the stock trading below key moving averages and negative MACD. Valuation is not supportive because the negative P/E reflects losses and there is no dividend yield provided.
TMS Co., Ltd. (4891) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.50B
Dividend YieldN/A
Average Volume (3M)256.91K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.36
Shares Outstanding45,485,767
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-15.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥620.00Price Target Upside380.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMS Co., Ltd. Business Overview & Revenue Model
Company DescriptionTMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
How the Company Makes Money
TMS Co., Ltd. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.95B | 0.00 |
| Gross Profit | -501.00K | -3.71M | -6.95M | -6.60M | 1.95B | -4.09M |
| EBITDA | -1.02B | -655.89M | -937.00M | -854.88M | 1.14B | -717.89M |
| Net Income | -699.20M | -660.55M | -960.04M | -860.92M | 1.08B | -722.93M |
Balance Sheet | ||||||
| Total Assets | 3.21B | 3.03B | 3.55B | 3.79B | 2.74B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 3.18B | 2.92B | 3.45B | 3.58B | 2.60B | 1.11B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 122.98M | 216.78M | 97.69M | 76.16M | 286.78M | 86.38M |
| Stockholders Equity | 3.09B | 2.82B | 3.46B | 3.71B | 2.45B | 1.13B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -524.60M | -826.17M | -702.14M | 1.25B | -738.31M |
| Operating Cash Flow | 0.00 | -493.76M | -822.81M | -688.42M | 1.26B | -737.81M |
| Investing Cash Flow | 0.00 | -30.84M | -3.36M | -13.72M | -16.96M | -499.00K |
| Financing Cash Flow | 0.00 | 919.00K | 688.13M | 1.69B | 246.48M | 1.10B |
TMS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | ¥6.87B | -5.79 | ― | 5.44% | -15.42% | -879.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ¥8.47B | -6.22 | ― | ― | 5.44% | -2.17% | |
45 Neutral | ¥7.69B | -4.18 | ― | ― | -93.79% | -1332.86% | |
44 Neutral | ¥6.50B | -9.11 | ― | ― | ― | ― | |
43 Neutral | ¥6.32B | -8.08 | ― | ― | -12.01% | 26.66% |
* Healthcare Sector Average
JP:4891
TMS Co., Ltd.
143.00
-67.00
-31.90%
DE:30O
OncoTherapy Science
0.11
0.01
13.98%
JP:2183
Linical Co., Ltd.
304.00
-38.91
-11.35%
JP:2370
MEDINET Co., Ltd.
32.00
-3.00
-8.57%
JP:3750
Cytori Cell Research Institute, Inc.
861.00
-26.00
-2.93%
JP:4893
Noile-Immune Biotech Inc.
146.00
-42.00
-22.34%
TMS Co., Ltd. Corporate Events
TMS Co., Ltd. Reports Financial Losses for Six Months Ending August 2025
Oct 15, 2025
TMS Co., Ltd. reported its non-consolidated financial results for the six months ended August 31, 2025, showing a decline in operating income and net income compared to the previous year. Despite the financial losses, the company’s equity-to-asset ratio improved to 94.9% from 92.1% as of February 28, 2025, indicating a stronger financial position. The company did not declare any dividends for the period and has not provided a forecast for the fiscal year ending December 31, 2025, due to difficulties in reasonably calculating financial results.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.